Andy Batts
Long only, value, growth, momentum

Qiagen: Why I Prefer Waiting On The Sidelines

Netherlands-based Qiagen N.V. (NASDAQ:QGEN) is a leading global provider of sample and assay technologies. The company aims to accelerate growth in 2014 primarily by boosting the global adoption of its QIAsymphony platform and establishing the QuantiFeron-TB platform as the modern gold standard for latent tuberculosis control. In this article I will analyze whether these initiatives are enough for boosting shareholder value amid an extremely tough competitive environment.

QuantiFeron-TB Gold

Tuberculosis ("TB") is caused by the intracellular pathogen Mycobacterium tuberculosis ("MTB"). In 2011, Qiagen took over Australia's Cellestis, the company that developed QuantiFeron-TB, an FDA-approved interferon-gamma release assay ("IGRA") for the detection of tuberculosis infection. Qiagen has big plans for the QuantiFeron-TB Gold and its variant QuantiFeron-TB Gold In...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
WITH SEEKING ALPHA PRO, INVESTORS CAN ALSO:
  • Access Top Ideas, chosen by Seeking Alpha’s editors
  • Filter long and short ideas by market cap and sector
  • Get Coverage of over 5,000 stocks, many of which have little or no coverage elsewhere
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO." Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else." Patrick Rice, Mainstay Capital Management
100% Satisfaction Guaranteed
Money back guarantee. Seeking Alpha PRO members receive a no-questions-asked refund for membership on months paid and not used. Details